Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STSP-0601 dose escalation in inhibitory hemophilia
NCT04747964Phase 1Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Jan 2020
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bemiltenase alfa in hemophilia A and hemophilia B (HB) (6 arms), sponsored by Staidson Biopharmaceutical. Primary endpoints: Number of subjects of adverse events, Number of subjects With Significant Abnormal Physical Examination and 3 more. Started Jan 2020; status: completed.
02
Drugs
bemiltenase alfa
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT04747964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04747964.